The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches

被引：9
作者：
Kizaki, Masahiro [1 ]
Tabayashi, Takayuki [1 ]
机构：
[1] Saitama Med Univ, Saitama Med Ctr, Dept Hematol, 1981 Kamoda, Kawagoe, Saitama 3508550, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2016年 / 56卷 / 01期
关键词：
multiple myeloma; cytokines; signaling pathway; molecular-targeted therapy;
D O I：
10.3960/jslrt.56.20
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The introduction of novel agents, such as bortezomib, thalidomide, and lenalidomide, into daily practice has dramatically improved clinical outcomes and prolonged survival of patients with multiple myeloma (MM). However, despite these advanced clinical benefits, MM remains an incurable hematological malignancy. Therefore, development of new agents and novel therapeutic strategies is urgently needed. Recent advances toward understanding the mechanism of myeloma cell growth and drug resistance in the bone marrow milieu have provided clues for the development of next-generation agents aimed at improving patient outcomes. In this review article, we discuss new possible agents for the treatment of MM based on recent advances in the understanding of signaling pathways in myeloma cells. [J Clin Exp Hematop 56(1):20-27, 2016]
引用
收藏
页码：20 / 27
页数：8
相关论文
共 58 条
[51]   Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma [J].
Siegel, D. S. ;
Richardson, P. ;
Dimopoulos, M. ;
Moreau, P. ;
Mitsiades, C. ;
Weber, D. ;
Houp, J. ;
Gause, C. ;
Vuocolo, S. ;
Eid, J. ;
Graef, T. ;
Anderson, K. C. .
BLOOD CANCER JOURNAL, 2014, 4 :e182-e182
[52]   Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program [J].
Siegel, David S. ;
Jagannath, Sundar ;
Hajek, Roman ;
Dimopoulos, Meletios A. ;
Yoon, Sung-Soo ;
Lonial, Sagar ;
Laubach, Jacob P. ;
Graef, Thorsten ;
Pietrangelo, Dina ;
Lupinacci, Lisa ;
Reiser, David ;
Anderson, Kenneth C. .
BLOOD, 2010, 116 (21) :813-814
[53]   Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival [J].
Steinbrunn, Torsten ;
Stuehmer, Thorsten ;
Gattenloehner, Stefan ;
Rosenwald, Andreas ;
Mottok, Anja ;
Unzicker, Christian ;
Einsele, Hermann ;
Chatterjee, Manik ;
Bargou, Ralf C. .
BLOOD, 2011, 117 (06) :1998-2004
[54]   Targeting cancer stem cells by inhibiting Wnt, notch, and Hedgehog pathways [J].
Takebe, Naoko ;
Harris, Pamela J. ;
Warren, Ronald Q. ;
Ivy, S. Percy .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (02) :97-106
[55]   Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma [J].
Vanderkerken, Karin ;
Medicherla, Satya ;
Coulton, Les ;
De Raeve, Hendrik ;
Willems, Angelo ;
Lawson, Michelle ;
Van Camp, Ben ;
Protter, Andrew A. ;
Higgins, Linda S. ;
Menu, Eline ;
Croucher, Peter I. .
CANCER RESEARCH, 2007, 67 (10) :4572-4577
[56]   Current approaches for the treatment of multiple myeloma [J].
Watanabe, Reiko ;
Tokuhira, Michihide ;
Kizaki, Masahiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (03) :333-344
[57]   HSP90 and the chaperoning of cancer [J].
Whitesell, L ;
Lindquist, SL .
NATURE REVIEWS CANCER, 2005, 5 (10) :761-772
[58]   Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups:: Akt-dependent and Akt-independent multiple myeloma [J].
Zoellinger, Angela ;
Stuehmer, Thorsten ;
Chatterjee, Manik ;
Gattenloehner, Stefan ;
Haralambieva, Eugenia ;
Mueller-Hermelink, Hans-Konrad ;
Andrulis, Mindaugas ;
Greiner, Axel ;
Wesemeier, Carmen ;
Rath, Joerg C. ;
Einsele, Hermann ;
Bargou, Ralf C. .
BLOOD, 2008, 112 (08) :3403-3411
123456